Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer

CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update

“…Currently, in men with CRPC, phase III clinical trials evaluating whether prednisone and abiraterone acetate, a potent and irreversible inhibitor of CYP-17, a critical enzyme in androgen biosynthesis, can improve survival when compared to prednisone and placebo have been published. [5][6][7][8] In the post-docetaxel setting, abiraterone/prednisone was shown to significantly prolong median overall survival compared to placebo/prednisone by 3.9 months to 14.8 versus 10.9 months (hazard ratio [HR] 0.64, p = 0.0001). Abiraterone acetate was also shown to improve patient-reported outcomes (pain, quality of life) and delay skeletal-related events (SREs).…”

Three Dimensional Tissue Models for Research in Oncology

“…And recently, abiraterone, an inhibitor of CYP17A, revealed some progress in the treatment of castration-resistant prostate cancer by complete blocking of androgen synthesis. Prostate cancer depends to 80 percent on androgen the biosynthesis of which is catalyzed in the last step by the P450 enzyme CYP17A both in testes and in adrenals (Hartmann et al, 2002;Reid et al, 2010). Understanding the molecular epidemiology of human tumors should help to promote the development of agents against such host factors.…”

Management of Castration-Resistant Prostate Cancer: A Global Approach

“…Currently, phase iii clinical trials in men with crpc, evaluating whether, compared with prednisone and placebo, prednisone and abiraterone acetate-a potent and irreversible inhibitor of CYP17, which is a critical enzyme in androgen biosynthesis-can improve survival, have recently completed accrual 7 . In the postdocetaxel setting, abiraterone-prednisone (compared with placebo-prednisone) was shown to significantly prolong median overall survival by 3.9 months [14.8 months vs. 10.9 months; hazard ratio (hr): 0.64; p = 0.0001] 8 .…”